Board of Directors

He is the Chairman of Owlstone Medical Ltd, Ieso Digital Health Ltd and Congenica Ltd, and is a director of RNAvate and Our Future Health Trading, as well as being a council member of the UKRI Medical Research Council.

Andrew has a Ph.D. in Chemistry from Cambridge and was a founder of Chiroscience in 1992 and an Executive Director through to the Celltech deal in 1999. Andrew has a track record as a founder, active investor in, and director of, more than 25 innovative healthcare and life-science companies, including Vectura plc and Arakis Ltd. He is an experienced board director for several public companies, including Chiroscience plc, Vectura plc, IXICO plc and Silence Therapeutics plc.

Through her leadership, Arecor has grown significantly into a publicly listed clinical stage biopharmaceutical company. Since her appointment, Sarah has led Arecor through a period of continued growth and transformation, playing an instrumental role in progressing its proprietary pipeline and strengthening important collaborations with global partners.

Sarah has a background in clinical and commercial pharmaceutical product development, manufacturing, supply and licensing across a range of product types and therapeutic areas, with previous senior roles in the pharmaceutical industry including Vice President CMC & Technical Development at BTG Plc., and Director of Outsourced Manufacturing at UCB-Celltech. Sarah holds a BSc in Chemistry from the University of Birmingham and a Ph.D. in Physical Organic Chemistry from the University of St Andrews.

He was appointed as interim Chief Financial Officer (CFO) in November 2024, became full time CFO in February 2025. He was appointed as an Executive Director in September 2025. Before joining Arecor, he has held CFO roles at numerous healthcare companies including Sixfold Bioscience, Silence Therapeutics, and Juvenescence. He qualified as a Chartered Accountant at PwC.

Currently, he is Director of Research, Global Industries at Bloomberg Intelligence in London, where he specialises in global pharmaceuticals.

Prior to joining Bloomberg in 2010, Sam worked at Piper Jaffray, Ltd. as a pharmaceutical analyst and head of European research. Before transitioning to investment banking, he was a research scientist for seven years. Sam has been ranked a top analyst by both the UK and Pan-European Extel surveys. He holds a degree from Cardiff University, and a Ph.D. in Pharmacology from the University of London.

He is an experienced Pharmaceutical and Biotech General Manager, having been responsible for product development and market access, as well as commercial strategy development and product launches at a national, regional and global level.

Jeremy was Vice President of Diabetes, International, for Eli Lilly & Company from 2014-2017, leading and developing individuals and teams across Europe, Japan, Canada and Australia and working across functions, geographies and products. From 2018-2019 Jeremy served as Chief Operating Officer at market access and reimbursement specialists PHMR Limited, where he was also Non-Executive Chairman from 2019-2020. He is currently President, Kyowa Kirin International plc.

In his c.30 years at PwC, of which more than half was spent as a partner, he specialised in financial accounting, reporting, auditing and risk management, focusing on the growth companies in the life sciences and technology sectors.  He has a strong track record of assisting both private and public companies to achieve their strategic ambitions, preparing for IPO and M&A transactions and strengthening governance.  His clients included those listed on AIM and the main market of the London Stock Exchange, as well as on other European and US exchanges. He qualified as a Chartered Accountant at PwC.